Jardiance and Venclexta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Jardiance (empagliflozin) and Venclexta (venetoclax). Common drug interactions include acute myeloid leukaemia recurrent among females and neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Jardiance and Venclexta. It is created by eHealthMe based on reports of 91 people who take the same drugs from the FDA, and is updated regularly.

What is Jardiance?

Jardiance has active ingredients of empagliflozin. It is often used in hyperglycemia. eHealthMe is studying from 44,457 Jardiance users. Check the latest studies of Jardiance.

What is Venclexta?

Venclexta has active ingredients of venetoclax. eHealthMe is studying from 31,425 Venclexta users. Check the latest studies of Venclexta.

On Jul, 19, 2026

91 people who take Jardiance and Venclexta together, and have interactions are studied.

Jardiance and Venclexta drug interactions.

What are the common drug interactions of Jardiance and Venclexta, by gender? *:

female:

Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
Confusional state
Haemorrhage (bleeding)
Nausea (feeling of having an urge to vomit)
Platelet disorder
Urinary tract infection
Abdominal discomfort
Acute respiratory failure
Adverse drug reaction
Asthenia (weakness)

male:

Neutropenia (an abnormally low number of neutrophils)
Diarrhoea
Disease progression
Viral infection
Anal abscess
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Dizziness
Death
Muscular weakness (muscle weakness)
Weight decreased

What are the common drug interactions of Jardiance and Venclexta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Staphylococcal infection (an infection with staphylococcus bacteria)

50-59:

Flatulence (flatus expelled through the anus)
Chronic lymphocytic leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell))
Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)
Thrombocytopenia (decrease of platelets in blood)
Disease progression
Death
Bacterial sepsis
Escherichia infection (bacterial infection by escherichia coli)
Fistula (an abnormal connection or passageway between two)
Influenza

60+:

Neutropenia (an abnormally low number of neutrophils)
Diarrhoea
Weight decreased
Abdominal pain
Angiopathy (generic term for a disease of the blood vessels)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Cardiac fibrillation (uncontrolled muscle contraction of heart)
Carotid artery stenosis (narrowing of carotid artery)
Gout (uric acid crystals building up in the body)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 31 people, 34.07%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 30 people, 32.97%
Diabetes: 13 people, 14.29%
High Blood Pressure: 9 people, 9.89%
Multiple Myeloma (cancer of the plasma cells): 8 people, 8.79%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 6 people, 6.59%
Type 2 Diabetes: 5 people, 5.49%
Pain: 5 people, 5.49%

* Approximation only. Some reports may have incomplete information.

Do you take Jardiance and Venclexta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously